Leveraging T cell co-stimulation for enhanced therapeutic efficacy of trispecific antibodies targeting prostate cancer
Open Access
- 13 March 2025
- journal article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (3) , e010140
Abstract
Background: Clinical trials have demonstrated the efficacy of bispecific antibodies in eliciting potent antitumor responses by redirecting T cells to target cancer cells, particularly for the treatment of hematologic malignancies. However, their efficacy against solid tumors is limited by intratumoral T-cell dysfunction and inadequate persistence. The co-stimulatory domains of 4-1BB, OX40, and CD28 are most widely used in engineering chimeric antigen receptor T-cells to augment T-cell responses. Methods: In this study, we designed three co-stimulatory trispecific T cell-engaging antibodies (TriTCEs) that target Prostate-specific membrane antigen, CD3, and an additional co-stimulatory receptor(OX40, 4-1BB, or CD28). We conducted comparative profiling of the attributes of distinct co-stimulatory signals to T-cell functions in prostate cancer models. Results: Co-stimulatory trispecific T-cell engagers enhance T-cell activation, proliferation, and display tumor cell-killing activity in vitro. These trispecific antibodies further boosted antitumor activity in humanized mouse xenograft models and increased the infiltration of CD45+ immune cells into solid tumors. Specifically, TriTCE-4-1BB and TriTCE-CD28 selectively promoted the expansion of effector memory T cells and increased the presence of CD4+ T cells more than TriTCE-OX40. T cells stimulated with TriTCE-4-1BB exhibited reduced exhaustion. Furthermore, T cells treated with co-stimulatory trispecific antibodies demonstrated enhanced metabolic activity characterized by increased oxidative phosphorylation and elevated glycolysis. Conclusions: Collectively, incorporating co-stimulatory receptor targeting domains represents a potentially effective strategy to unlock the full therapeutic potential of T-cell-engaging antibodies for the treatment of solid tumors.Keywords
Funding Information
- National Natural Science Foundation of China (82073750, 82473824, U20A20409)
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases (Grant No. zz202303)
- National Key Research and Development Program of China (2023YFC3403900)
This publication has 34 references indexed in Scilit:
- Immune checkpoint therapy—current perspectives and future directionsCell, 2023
- OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrumCell Reports Medicine, 2023
- Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analysesNature Communications, 2023
- Current Clinical Trial Landscape of OX40 AgonistsCurrent Oncology Reports, 2022
- How to turn up the heat on the cold immune microenvironment of metastatic prostate cancerProstate Cancer and Prostatic Diseases, 2021
- The promise and challenges of immune agonist antibody development in cancerNature Reviews Drug Discovery, 2018
- T Cell Dysfunction in CancerCancer Cell, 2018
- CD28 Costimulation: From Mechanism to TherapyImmunity, 2016
- Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responsesEuropean Journal of Immunology, 2002
- In Vitro Characterization of Five Humanized OKT3 Effector Function Variant AntibodiesCellular Immunology, 2000